Compass HealthAI offers the RestoRx™ Low Vision System, a non‑invasive corneal laser that redirects light to healthier peripheral macular tissue, widening the area of sharp focus and allowing patients with late‑stage AMD or central vision loss to regain reading ability, facial recognition, and independence. The painless, sub‑second procedure can be performed in standard retina or refractive clinics without downtime, and has demonstrated safety and visual acuity improvements in over 500 treated eyes across multiple countries.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with late-stage age‑related macular degeneration (AMD) and other central vision loss conditions experience severe blur in the central visual field, limiting reading, facial recognition, and independent navigation. Existing therapies focus on slowing disease progression but do not restore lost central vision, leaving patients dependent and reducing quality of life.
Solution
Compass HealthAI offers the RestoRx™ Low Vision System, a non‑invasive corneal laser that gently redirects incoming light toward healthier peripheral regions of the macula. By widening the area of sharp focus, the system enables the brain to adapt and use these peripheral zones for detailed vision, reducing central blur. The procedure is painless, takes less than a second, and requires no recovery time, allowing treatment in standard retina or refractive clinics. When combined with patients’ ongoing retinal health management (e.g., anti‑VEGF injections and lifestyle care), RestoRx can produce measurable improvements on eye charts and quality‑of‑life scores, helping patients regain reading ability, facial recognition, and greater independence.
Target Audience
Primary customers are ophthalmologists, retina specialists, and low‑vision rehabilitation clinics that treat patients with AMD‑related central vision loss, as well as the patients themselves seeking vision restoration.
Features
- Patented corneal laser technology that redirects light to functional macular tissue without tissue ablation
- Procedure duration under one second, painless, and without post‑treatment downtime
- Compatible with routine clinic workflows; no specialized surgical suite required
- Demonstrated safety in over 500 treated eyes across seven countries with no reported adverse events
- Clinical outcomes include multiple lines of visual acuity improvement and enhanced quality‑of‑life metrics
- Requires a healthy peripheral macula (within 10° eccentricity) and adherence to existing retinal therapies for optimal results